The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2022 | Clinical significance of Ig gene mutations in CLL
Andreas Agathangelidis, PhD, Center for Research and Technology Hellas, Thermi, Greece, highlights the importance of mutations in the immunoglobulin (Ig) gene as a prognostic marker in chronic lymphocytic leukemia (CLL), with an emphasis on using appropriate protocols and correctly interpreting genomic tests. Dr Agathangelidis also notes that uncommon cases are more difficult to analyze and require more attention. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
